Veracyte(US:VCYT)2025-11-04 21:30Financial Performance - Total revenue increased to $132 million in Q3 2025, a 14% year-over-year growth compared to $116 million in Q3 2024[10] - Testing revenue reached $128 million in Q3 2025, a 17% year-over-year increase from $110 million in Q3 2024[10] - Adjusted EBITDA margin was 30.1% in Q3 2025, compared to 23.6% in Q3 2024[34] - The company raised full-year revenue guidance to $506 - $510 million and adjusted EBITDA margin expectations to over 25%[36] - Cash and short-term investments increased to $366 million at the end of Q3 2025, compared to $274 million in Q3 2024[34] Testing Volume and Growth - Testing volume increased to 43,700 in Q3 2025, a 19% year-over-year growth compared to 36,800 in Q3 2024[10] - Decipher test quarterly volume continued to grow, with a 26% increase[16] - Afirma test quarterly volume also experienced growth, with a 13% increase[21] Strategic Initiatives and Product Development - The company is transitioning to v2 Veracyte transcriptome to improve operational efficiency[14] - Commercial launch of TrueMRD for muscle invasive bladder cancer (MIBC) is on track for the first half of 2026[25] - Prosigna LDT launch is on track for mid-2026 in the CLIA lab[26]